Cisplatin, mitomycin, and interferon-alpha 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

Metintas M., Ozdemir N., Ucgun I., Elbek O., Kolsuz M., Mutlu S., ...More

CHEST, vol.116, no.2, pp.391-398, 1999 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 116 Issue: 2
  • Publication Date: 1999
  • Doi Number: 10.1378/chest.116.2.391
  • Journal Name: CHEST
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.391-398
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Study objective: To investigate the therapeutic activity and toxicity of combination chemoimmunotherapy with cisplatin, mitomycin, and interferon (IFN)-alpha 2a, by comparing the responses in a group of patients with diffuse malignant pleural mesothelioma (DMPM) to the responses in a control group of DMPM patients given supportive care alone.